Clinical trials of mAbs grown more than 100 percent

Clinical trials of monoclonal antibodies (mAb), have grown 115% globally in the ten year period 2007–2016 according to GlobalData, a leading data and analytics company

The company tracks clinical trials activity across the world and has identified 5273 industry mAb clinical trials between 1 January 2007 and 31 December 2016.

In 2015, the most prominent increase in new clinical trials of mAbs, 26%, occurred.

A small number of Phase 0, Phase I/II, Phase II/III and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.

Overall, Phase II trials outnumbered all other trials by contributing between 31% and 46% across the period.

A spokesperson from the GlobalData Pharma analyst team, said: “The share of Phase I trials started at 18% in 2007 and increased to 27% by 2016. Phase III trials’ contribution remained flat at an average of 24% across the 10 year period, whereas Phase IV trials decreased in share from 13% to 12% in the first and last years, respectively.”

Companies